LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Simulations Plus Inc

Fermé

SecteurSoins de santé

11.37 -6.42

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.11

Max

11.6

Chiffres clés

By Trading Economics

Revenu

1.4M

676K

Ventes

961K

18M

P/E

Moyenne du Secteur

48.528

110.024

BPA

-0.034

Rendement du dividende

0.48

Marge bénéficiaire

3.67

Employés

212

EBITDA

-3M

2.3M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+62.95% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.48%

2.26%

Prochains Résultats

2 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-120M

248M

Ouverture précédente

17.79

Clôture précédente

11.37

Sentiment de l'Actualité

By Acuity

50%

50%

149 / 351 Classement par Healthcare

Simulations Plus Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 févr. 2026, 22:36 UTC

Résultats

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 févr. 2026, 22:32 UTC

Résultats

Woodside Energy Fiscal Year Net Profit Falls 24%

23 févr. 2026, 23:58 UTC

Market Talk
Résultats

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 févr. 2026, 23:58 UTC

Market Talk
Résultats

Global Energy Roundup: Market Talk

23 févr. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 févr. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 févr. 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

Crescent Capital Partners Owns 53% of ClearView Wealth

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 févr. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 févr. 2026, 23:39 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 févr. 2026, 23:31 UTC

Résultats

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 févr. 2026, 23:31 UTC

Résultats

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 févr. 2026, 23:27 UTC

Résultats

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 févr. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 févr. 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 févr. 2026, 22:31 UTC

Résultats

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 févr. 2026, 22:24 UTC

Résultats

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Underlying Ebitda A$700.9 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 févr. 2026, 22:21 UTC

Résultats

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 févr. 2026, 22:21 UTC

Résultats

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 févr. 2026, 22:20 UTC

Résultats

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparaison

Variation de prix

Simulations Plus Inc prévision

Objectif de Prix

By TipRanks

62.95% hausse

Prévisions sur 12 Mois

Moyen 19 USD  62.95%

Haut 19 USD

Bas 19 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

4 ratings

2

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

149 / 351Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat